Everyone agrees that minimal residual disease (MRD) is the best prognostic tool for multiple myeloma, but there is disagreement on how to use the MRD results, said Ajay Nooka, MD, MPH, FACP, associate professor, Winship Cancer Institute.
Everyone agrees that minimal residual disease (MRD) is the best prognostic tool for multiple myeloma, but there is disagreement on how to use the MRD results, said Ajay Nooka, MD, MPH, FACP, associate professor, Winship Cancer Institute.
Transcript
A recent study found minimal residual disease (MRD) testing has rapidly gained acceptance. What has been the experience at Emory?
This is a good question. You asked 5 different people, you get 5 different answers. The study that you're referring to was published in Blood Advances. This study was seeking the myeloma experts opinions of how would they use MRD. The approval for MRD testing in myeloma was not for any specific indication—it got an approval. It is left up to the investigator or the clinician to figure out how to use this test, which is becoming the biggest challenge, and which led us to a lot of heterogeneous opinions on how to use the test.
The one thing that I will clearly, confidently say, which most of my colleagues agree, would be: it is the best prognostic test that we have at this point of time. We're able to measure those depths of responses. Achieving MRD negativity of 10-6 is an independent prognostic factor for both the progression-free survival as well as overall survival. We can confidently say that. But when you ask opinions about: how do you use this test for the treatment discontinuations or treatment continuations, it becomes a slippery slope there, because it is all left up to the subjectivity and the decision of the individual.
The same study found that depending on the results of MRD testing, clinicians may intensify or decide to de-escalate therapy. Is one more common than the other at Emory?
We typically don't make any changes at this point of time. We want to build upon the data to make it really beneficial for the patient. We don't want to stop a treatment with a short-term end point. I view achieving MRD negativity as extremely dynamic. You see the changes, you achieve that negativity, you lose that negativity, as well. At any certain point of time, making a treatment decision based on MRD negativity at a certain point of time at this point, I believe is very immature, and this is what has been shown in a lot of trials that are ongoing. There is a role for sustained MRD negativity with a period of time in between lasting 6 months or a year, where you're able to show that MRD negativity levels at 2 different time points, with a duration of time in between, and that potentially will have a better utility than using MRD at a single point of time.
Dr Dalia Rotstein: Physicians Must Be Aware MS Affects People of All Backgrounds
April 24th 2024Dalia Rotstein, MD, MPH, emphazises the importance of awareness that multiple sclerosis (MS) impacts patients from various backgrounds as clinicians think through ways to improve access to care and research efforts in MS.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Dr Michael Farwell on FDG PET/CT Imaging to Predict Immunotherapy Response in Advanced Melanoma
April 15th 2024Michael Farwell, MD, associate professor of radiology at the Hospital of the University of Pennsylvania, provides insights into a study on the benefits of using 18F-fluorodeoxyglucose (FDG) PET/CT imaging to detect metabolic tumor changes in skin cancer.
Read More
Study Urges Personalized Care to Boost Quality of Life in Patients With MM
April 11th 2024Treatment and management of multiple myeloma (MM) is continuously evolving, and in this analysis, investigators discuss ever-present issues and potential solutions to optimize care for this patient population.
Read More